

December 28, 2016



VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference

NAMUR, Belgium, Dec. 28, 2016 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today announced that it will present at the 9th Annual Biotech Showcase Conference being held from January 9-11, 2017 in San Francisco, CA.

At the Biotech Showcase, Cameron Reynolds, Chief Executive Officer of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.Q™ Colorectal Cancer Screening Triage Test.

Event: 9th Annual Biotech Showcase Conference
Date: Tuesday, January 10, 2017
Time: 8:30 AM Pacific Time
Location: Room 8 (Ballroom Level), Hilton San Francisco Union Square Hotel, San Francisco, CA

The presentation will be webcast live and will be available on the Investor Relations page of Volition's website at <http://ir.volitionrx.com/>. The webcast will remain available for 90 days following the presentation.

About Volition

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition L.day@volitionrx.com +44 (0)7557 774620	Scott Powell, Volition S.powell@volitionrx.com +1 (646) 650 1351
Tirth Patel, Edison Advisors tpatel@edisongroup.com +1 (646) 653 7035	Rachel Carroll, Edison Advisors rcarroll@edisongroup.com +44 (0)20 3077 5711
Sarah Roberts, Vane Percy & Roberts sarah@vanepercy.com +44 (0)1737 821 890	

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-9th-annual-biotech-showcase-conference-300382614.html>

SOURCE VolitionRx Ltd.